Avancerad sökning
Visar resultat 1 - 5 av 144 avhandlingar som matchar ovanstående sökkriterier.
1. Glioblastoma heterogeneity and plasticity : Investigating the roles of BMP4 and SOX2
Sammanfattning : The malignant primary brain tumor glioblastoma has a dismal prognosis and is distinguished by its heterogeneous character. Current treatment with surgical resection, radiotherapy and adjuvant chemotherapy with the alkylating agent temozolomide does not provide a cure, but simply prolongs survival by a few months. LÄS MER
2. New Molecular Approaches to Glioblastoma Therapy
Sammanfattning : Glioblastoma (GBM) is the most common high-grade brain tumor diagnosed in patients who are more than 50 years of age. The standard of care treatment is surgery, followed by radiotherapy and chemotherapy. The median life expectancy of patients is only between 12 to 15 months after receiving current treatment regimes. LÄS MER
3. Tertiary lymphoid structures in glioblastoma : Discovery, Characterization and Therapeutic Induction
Sammanfattning : Glioblastoma (GBM) is an incurable brain cancer with a median survival of less than two years from diagnosis. The tumor microenvironment plays a major role in GBM progression through sustaining immunosuppression and poor lymphocytic infiltration. LÄS MER
4. Novel treatments of glioblastoma in experimental models
Sammanfattning : One of the major problems with malignant brain tumours, such as glioblastoma multiforme, is that despite being able to remove the major bulk of the tumour through surgery and treating the patients with chemotherapy and radiotherapy, we know that tumour cells have already spread throughout the brain. Furthermore, we now know that the glioblastoma cells effectively suppress the patients’ own anti-tumour response. LÄS MER
5. Modeling glioblastoma growth patterns and their mechanistic origins
Sammanfattning : Glioblastoma (GBM) is the most common and aggressive primary brain cancer. GBM cells migrate away from the primary lesion and invade healthy brain tissue. The invading cells escape surgical resection, radiotherapy and develop resistance to chemotherapy. Consequently, despite treatment, recurrence is inevitable, and survival is only 14 months. LÄS MER